CD37 and acute myeloid leukemia: Mice transplanted with CD37−/− LSCs exhibited a marked reduction in AML progression (Figure 5B), accompanied by reduced tumor infiltration (Figures 5C and S4H–S4J) and prolonged survival (Figure 5D), compared to those transplanted with CD37fl/fl LSCs.